Manipulation of a VEGF-Notch signaling circuit drives formation of functional vascular endothelial progenitors from human pluripotent stem cells

Correction to: Cell Research (2014) 24:820–841; doi:10.1038/cr.2014.59; published online 9 May 2014

The protocol in the current study was developed using BIO as the GSK-3β inhibitor and works with other inhibitors as well. The strength and specificity of inhibition can increase efficiency of Phase I. The authors apologize for the mistyped GSK-3β inhibitor that was used in these studies. We would like to correct this immediately, which is noted only in three sentences in separate places in the paper. This does not impact on any of the results or the protocol mentioned in the paper and the results stand as is.

— (P 823, right column, line 5-7) “Treatment with the GSK-3β inhibitors BIO (6-bromoindirubin-3′-oxime; Sigma) or CP21R7 (Roche) in phase 1...” should be “Treatment with the GSK-3β inhibitor BIO (6-bromoindirubin-3′-oxime; Sigma) in phase 1...”.

— (P 824, left column, line 3-7) “We also found that CP21R7 had more stable results unaffected by its lot number, compared to BIO, and therefore, we basically used CP21R7 as a GSK-3β inhibitor in phase 1 in the following experiments.” should be deleted.

— (Supplementary information, Table S1, line 27) “GSK-3β inhibitor (BIO/CP21R7) [1uM/5uM]” should be “GSK-3β inhibitor (BIO) [5uM]”.